一线治疗失败后直接诱导昏迷治疗癫痫持续状态的安全性与疗效:一项双中心研究
该回顾性研究分析了2017至2018年瑞士巴塞尔和日内瓦两家学术医疗中心收治的230例成人癫痫持续状态(SE)患者,其中205例在一线药物治疗后进行了治疗升级。27.3%的患者直接接受人工昏迷诱导,72.7%接受二线非麻醉性抗癫痫药物,后者中16.6%因二线治疗失败后续接受人工昏迷。多变量分析显示,年轻、存在惊厥发作及SE严重程度较高(STESS评分)与一线治疗后直接诱导昏迷的几率增加相关。与按指南升级治疗的患者相比,直接诱导昏迷的患者结局和并发症无差异,但SE持续时间及ICU和住院时间更短。
要点
- 一线治疗失败后直接诱导昏迷在超过四分之一的SE患者中实施,多见于年轻、有惊厥及病情更重者。
- 直接诱导昏迷未增加并发症,且与更短的SE持续时间及ICU和住院时间相关。
- 该研究提供III级证据支持一线治疗失败后早期诱导昏迷的安全性和潜在获益。
核心结论
- 一线治疗失败后早期诱导人工昏迷与更短的SE持续时间和ICU及住院时间相关,且不增加并发症。
研究设计与样本
- 回顾性评估2017至2018年瑞士巴塞尔和日内瓦两家学术医疗中心收治的所有成人SE患者的临床和电生理数据,共230例,其中205例在一线药物治疗后进行了治疗升级。
主要发现
- 205例治疗升级患者中,27.3%直接接受人工昏迷,72.7%接受二线非麻醉性抗癫痫药物,后者中16.6%后续因二线治疗失败接受人工昏迷。
- 多变量分析显示,年轻、存在惊厥发作及STESS评分较高的SE严重程度与一线治疗后直接诱导昏迷的几率增加相关。
- 与按指南升级治疗的患者相比,直接诱导昏迷的患者结局和并发症无差异,但SE持续时间及ICU和住院时间更短。
关键数值与推荐
- 直接诱导昏迷组与指南升级组在结局和并发症上无差异。
- 直接诱导昏迷与更短的SE持续时间、ICU停留时间和住院时间相关。
- 研究提供III级证据支持一线治疗失败后早期诱导昏迷的安全性和潜在获益。
临床怎么用
- 对于一线治疗失败的SE患者,尤其是年轻、有惊厥及病情较重者,可考虑早期诱导人工昏迷以缩短SE持续时间和住院时间。
- 早期诱导昏迷未增加并发症,可作为治疗升级的一种选择。
局限性
- 回顾性研究设计可能引入选择偏倚和信息偏倚。
- 样本来自两家瑞士学术医疗中心,结果外推需谨慎。
- 证据等级为III级,需进一步前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the safety and efficacy of artificial coma induction to treat status epilepticus (SE) immediately after first-line antiseizure treatment instead of following the recommended approach of first using second-line drugs. METHODS: Clinical and electrophysiologic data of all adult patients treated for SE from 2017 to 2018 in the Swiss academic medical care centers from Basel and Geneva were retrospectively assessed. Primary outcomes were return to premorbid neurologic function and in-hospital death. Secondary outcomes were the emergence of complications during SE, duration of SE, and intensive care unit (ICU) and hospital stays. RESULTS: Of 230 patients, 205 received treatment escalation after first-line medication. Of those, 27.3% were directly treated with artificial coma and 72.7% with second-line nonanesthetic antiseizure drugs. Of the latter, 16.6% were subsequently put on artificial coma after failure of second-line treatment. Multivariable analyses revealed increasing odds for coma induction after first-line treatment with younger age, the presence of convulsions, and an increased SE severity as quantified by the Status Epilepticus Severity Score (STESS). While outcomes and complications did not differ compared to patients with treatment escalation according to the guidelines, coma induction after first-line treatment was associated with shorter SE duration and ICU and hospital stays. CONCLUSIONS: Early induction of artificial coma is performed in more than every fourth patient and especially in younger patients presenting with convulsions and more severe SE. Our data demonstrate that this aggressive treatment escalation was not associated with an increase in complications but with shorter duration of SE and ICU and hospital stays. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that early induction of artificial coma after unsuccessful first-line treatment for SE is associated with shorter duration of SE and ICU and hospital stays compared to the use of a second-line nonanesthetic antiseizure drug instead of or before anesthetics, without an associated increase in complications.
引用
- De Stefano P, Baumann SM, Semmlack S, et al. Safety and Efficacy of Coma Induction Following First-Line Treatment in Status Epilepticus: A 2-Center Study. Neurology. 2021. PMID: 34045273. doi:10.1212/WNL.0000000000012292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。